Floatz logo

5-PYRIMIDINECARBOXAMIDE, 2-((1,1-DIMETHYLETHYL)AMINO)-4-(((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYL)AMINO)-

Respiratory System Disorder

CelgeneSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Respiratory System Disorder cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 3BB
.Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio-
Ziekenhuis Oost-Limburg
Phase 4BB
Rocuronium Ion
Ziekenhuis Oost-Limburg
Phase 4BB
Neostigmine
Coastal Anesthesiology Consultants
Phase 4BB
Pralsetinib, Trans-
Hoffmann-La Roche
Phase 3BB

View all 31 →

Same molecule, other indications

5-PYRIMIDINECARBOXAMIDE, 2-((1,1-DIMETHYLETHYL)AMINO)-4-(((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYL)AMINO)- is also rated in:

idiopathic interstitial pneumoniaDormant
CCC
Indicative · Phase 2
53 / 100
View asset →
interstitial lung diseaseDormant
CCC
Indicative · Phase 2
53 / 100
View asset →
lung disorderDormant
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →